Differentiating the third generation of antipsychotics: a focus on lumateperone’s similarities and differences

Abstract

The development of atypical antipsychotics has evolved to include newer pharmacodynamic properties. Lumateperone, aripiprazole, brexpiprazole, and cariprazine are all dopamine-2 receptor partial agonists with varying receptor affinities. This review aims to compare the clinical and pharmacodynamic differences among these four atypical antipsychotics, all of which are unique when compared to first- and second-generation antipsychotics. For consideration is further delineating these agents as being third-generation antipsychotics. PubMed searches were conducted to compile preclinical and clinical studies derived from animal models and human subjects. Information gathered included pharmacological mechanisms, clinical efficacy, future-oriented clinical approaches, and adverse effects. Efficacy for the shared indications of these drugs seems comparable. Differences among these drugs lie more in their adverse effect profiles. For example, lumateperone was found to have the lowest rate of weight gain while brexpiprazole was found to have the highest rate of weight gain associated with increased appetite. Aripiprazole had the lowest rates of extrapyramidal symptoms not including akathisia while cariprazine had the highest. All four agents reviewed have a variety of receptor affinities, which likely generates a variety of different adverse effects. This suggests that in any given patient, clinicians may see differential clinical effects.

Focus on antipsychotics and related therapeutic drug monitoring

“…Several new antipsychotics have been approved in recent years, and information on their most appropriate use is urgently needed. A review in this issue is a perfect example of what is needed to inform clinicians about new available treatments (Munayco Maldonado and Schwartz, 2023). In addition to the previously mentioned cariprazine, lumateperone and brexpiprazole have recently been approved for a range of indications.…”